Somatic mutation of KIT is rare in small cell lung cancer patients from Northeast China

Histology and Histopathology

Volumn 29, Issue 2, 2014, Pages 273-278

  Xuan, Hong ^a   Jingshu, Geng ^a   Fang, Yang ^a   Na, Li ^a   Xiaolin, Sheng ^a   Zhaoyang, Yang ^a   Meng, Wang ^a   Gongyan, Chen ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

KIT; Mutation; Protein expression; Small cell lung cancer

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHINA; FEMALE; GENETIC ASSOCIATION; GENETICS; GENOTYPE; HUMAN; LUNG SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SMALL CELL LUNG CARCINOMA; YOUNG ADULT;

EID: 84892768799     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bachet J.B., Hostein I., Le Cesne A., Brahimi S., Beauchet A., Tabone-Eglinger S., Subra F., Bui B., Duffaud F., Terrier P., Coindre J.M., Blay J.Y. and Emile J.F. (2009). Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br. J. Cancer 101, 7-11.
2. rd, Azar S., Rubin B.P., Muller S., West R., Heinrich M.C. and Corless C.L. (2008). KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828.
3. Boldrini L., Ursino S., Gisfredi S., Faviana P., Donati V., Camacci T., Lucchi M., Mussi A., Basolo F., Pingitore R. and Fontanini G. (2004). Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin. Cancer Res. 15, 4101-4108.
4. Brigham B.A., Bunn P.A Jr, Minna J.D., Cohen M.H., Ihde D.C. and Shackney S.E. (1978). Growth rates of small cell bronchogenic carcinomas. Cancer 42, 2880-2886.
5. Burger H., den Bakker M.A., Stoter G., Verweij J. and Nooter K. (2003). Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur. J. Cancer. 39, 793-799.
6. Camps C., Sirera R., Bremnes R.M., Garde J., Safont M.J., Blasco A., Berrocal A., Sánchez J.J., Calabuig C. and Martorell M. (2006). Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications. Lung Cancer 52, 343-347.
7. Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P. and De Sepulveda P. (2011). Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J. Biol. Chem. 286, 5956-5966.
8. Charpin C., Giusiano S., Charfi S., Secq V., Carpentier S., Andrac L., Lavaut M.N., Allasia C., Bonnier P. and Garcia S. (2009). Quantitative immunohistochemical expression of c-Kit in breast carcinomas is predictive of patients' outcome. Br. J. Cancer 101, 48-54.
9. Decaudin D., de Cremoux P., Sastre X., Judde J.G., Nemati F., Tran-Perennou C., Fréneaux P., Livartowski A., Pouillart P. and Poupon M.F. (2005). In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int. J. Cancer 113, 849-856.
10. Dowell J.E. (2010). Small cell lung cancer: are we making progress? Am. J. Med. Sci. 339, 68-76.
11. Dy G.K., Miller A.A., Mandrekar S.J., Aubry M.C., Langdon R.M Jr, Morton R.F., Schild S.E., Jett J.R. and Adjei A.A. (2005). A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. 16, 1811-1816.
12. Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W., DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L., Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X., Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M. and Demetri G.D. (2009). KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. USA 106, 1542-1547.
13. Guo J., Si L., Kong Y., Flaherty K.T., Xu X., Zhu Y., Corless C.L., Li L., Li H., Sheng X., Cui C., Chi Z., Li S., Han M., Mao L., Lin X., Du N., Zhang X., Li J., Wang B. and Qin S. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. 29, 2904-2909.
14. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., Kiese B., Eisenberg B., Roberts P.J., Singer S., Fletcher C.D., Silberman S., Dimitrijevic S. and Fletcher J.A. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349.
15. Jemal A., Bray F., Center M.M., Ferlay J., Ward E. and Forman D. (2011). Global cancer statistics.CA. Cancer J. Clin. 61, 69-90.
16. Kemmer K., Corless C.L., Fletcher J.A., McGreevey L., Haley A., Griffith D., Cummings O.W., Wait C., Town A. and Heinrich M.C. (2004). KIT mutations are common in testicular seminomas. Am. J. Pathol.164, 305-313.
17. Kong Y., Si L., Zhu Y., Xu X., Corless C.L., Flaherty K.T., Li L., Li H., Sheng X., Cui C., Chi Z., Li S., Han M., Mao L., Lu A. and Guo J. (2011). Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clin. Cancer. Res. 17, 1684-1691.
18. Krishnan S., Mali R.S., Koehler K.R., Vemula S., Chatterjee A., Ghosh J., Ramdas B., Ma P., Hashino E. and Kapur R. (2012). Class I(A) PI3Kinase regulatory subunit, p85α, mediates mast cell development through regulation of growth and survival related genes. PloS. One 7, e28979.
19. Lennartsson J., Blume-Jensen P., Hermanson M., Pontén E., Carlberg M. and Rönnstrand L. (1999). Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18, 5546-5553.
20. Lev S., Yarden Y. and Givol D. (1992). Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J. Biol. Chem. 267, 15970-15977.
21. Litz J., Sakuntala Warshamana-Greene G., Sulanke G., Lipson K.E. and Krystal G.W. (2004). The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46, 283-291.
22. Lu H.Y., Zhang G., Cheng Q.Y., Chen B., Cai J.F., Wang X.J., Zhang Y.P., Wang Z., Lu Z.Y., Xie F.J. and Mao W.M. (2012). Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol. Lett. 4, 89-93.
23. Micke P., Faldum A., Metz T., Beeh K.M., Bittinger F., Hengstler J.G. and Buhl R. (2002). Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer 37, 271-276.
24. Mojica W.D., Saxena R., Starostik P. and Cheney R.T. (2005). CD117+ small cell lung cancer lacks the asp 816->val point mutation in exon 17. Histopathology 47, 517-522.
25. Omholt K., Grafström E., Kanter-Lewensohn L., Hansson J. and Ragnarsson-Olding B.K. (2011). KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin. Cancer Res. 17, 3933-3942.
26. Potti A., Moazzam N., Ramar K., Hanekom D.S., Kargas S. and Koch M. (2003). CD117 (c-KIT) overexpression in patients with extensivestage small-cell lung carcinoma. Ann. Oncol. 14, 894-897.
27. Rohr U.P., Rehfeld N., Pflugfelder L., Geddert H., Müller W., Steidl U., Fenk R., Gräf T., Schott M., Thiele K.P., Gabbert H.E., Germing U., Kronenwett R. and Haas R. (2004). Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int. J. Cancer 111, 259-263.
28. Schneider B.J., Kalemkerian G.P., Ramnath N., Kraut M.J., Wozniak A.J., Worden F.P., Ruckdeschel J.C., Zhang X., Chen W. and Gadgeel S.M. (2010). Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. Clin. Lung Cancer 11, 223-227.
29. Sihto H., Sarlomo-Rikala M., Tynninen O., Tanner M., Andersson L.C., Franssila K., Nupponen N.N. and Joensuu H. (2005). KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J. Clin. Oncol. 23, 49-57.
30. Tamborini E., Bonadiman L., Negri T., Greco A., Staurengo S., Bidoli P., Pastorino U., Pierotti M.A. and Pilotti S. (2004). Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin. Cancer Res. 10, 8214-8219.
31. Verweij J., van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., Radford J., Le Cesne A., Hogendoorn P.C., di Paola E.D., Brown M. and Nielsen O.S. (2003). Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 39, 2006-2011.